146 related articles for article (PubMed ID: 17130156)
1. Use of thermolytic protective groups to prevent G-tetrad formation in CpG ODN type D: structural studies and immunomodulatory activity in primates.
Puig M; Grajkowski A; Boczkowska M; Ausín C; Beaucage SL; Verthelyi D
Nucleic Acids Res; 2006; 34(22):6488-95. PubMed ID: 17130156
[TBL] [Abstract][Full Text] [Related]
2. Design and development of thermolytic DNA oligonucleotide prodrugs.
Grajkowski A; Pedras-Vasconcelos J; Ausín C; Verthelyi D; Beaucage SL
Ann N Y Acad Sci; 2005 Nov; 1058():26-38. PubMed ID: 16394123
[TBL] [Abstract][Full Text] [Related]
3. Thermolytic CpG-containing DNA oligonucleotides as potential immunotherapeutic prodrugs.
Grajkowski A; Pedras-Vasconcelos J; Wang V; Ausín C; Hess S; Verthelyi D; Beaucage SL
Nucleic Acids Res; 2005; 33(11):3550-60. PubMed ID: 15972797
[TBL] [Abstract][Full Text] [Related]
4. Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs.
Flynn B; Wang V; Sacks DL; Seder RA; Verthelyi D
Infect Immun; 2005 Aug; 73(8):4948-54. PubMed ID: 16041009
[TBL] [Abstract][Full Text] [Related]
5. Solid-phase synthesis of thermolytic DNA oligonucleotides functionalized with a single 4-hydroxy-1-butyl or 4-phosphato-/thiophosphato-1-butyl thiophosphate protecting group.
Grajkowski A; Ausín C; Kauffman JS; Snyder J; Hess S; Lloyd JR; Beaucage SL
J Org Chem; 2007 Feb; 72(3):805-15. PubMed ID: 17253799
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
[TBL] [Abstract][Full Text] [Related]
7. CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine.
Klinman DM; Xie H; Ivins BE
Ann N Y Acad Sci; 2006 Oct; 1082():137-50. PubMed ID: 17145935
[TBL] [Abstract][Full Text] [Related]
8. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
9. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases.
Klinman DM; Klaschik S; Sato T; Tross D
Adv Drug Deliv Rev; 2009 Mar; 61(3):248-55. PubMed ID: 19272313
[TBL] [Abstract][Full Text] [Related]
10. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
Mutwiri G; Benjamin P; Soita H; Babiuk LA
Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
[TBL] [Abstract][Full Text] [Related]
11. Poly-guanosine strings improve cellular uptake and stimulatory activity of phosphodiester CpG oligonucleotides in human leukocytes.
Bartz H; Mendoza Y; Gebker M; Fischborn T; Heeg K; Dalpke A
Vaccine; 2004 Nov; 23(2):148-55. PubMed ID: 15531031
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.
Vollmer J; Krieg AM
Adv Drug Deliv Rev; 2009 Mar; 61(3):195-204. PubMed ID: 19211030
[TBL] [Abstract][Full Text] [Related]
13. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
14. CpG oligodeoxynucleotides as vaccine adjuvants in primates.
Verthelyi D; Kenney RT; Seder RA; Gam AA; Friedag B; Klinman DM
J Immunol; 2002 Feb; 168(4):1659-63. PubMed ID: 11823494
[TBL] [Abstract][Full Text] [Related]
15. CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection.
Verthelyi D; Gursel M; Kenney RT; Lifson JD; Liu S; Mican J; Klinman DM
J Immunol; 2003 May; 170(9):4717-23. PubMed ID: 12707351
[TBL] [Abstract][Full Text] [Related]
16. Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides.
Mutwiri G; van Drunen Littel-van den Hurk S; Babiuk LA
Adv Drug Deliv Rev; 2009 Mar; 61(3):226-32. PubMed ID: 19162103
[TBL] [Abstract][Full Text] [Related]
17. CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections.
Zimmermann S; Dalpke A; Heeg K
Int J Med Microbiol; 2008 Jan; 298(1-2):39-44. PubMed ID: 17716944
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory effects associated with a live vaccine against Leishmania major containing CpG oligodeoxynucleotides.
Wu W; Weigand L; Belkaid Y; Mendez S
Eur J Immunol; 2006 Dec; 36(12):3238-47. PubMed ID: 17109471
[TBL] [Abstract][Full Text] [Related]
19. [A study on the mechanisms of mycobacterial clearance induced by CpG-oligodeoxynucleotides in mice].
Ren T; Liang YJ; Cai YY; Li CY; Mei J; Yuan ZH; Tao MF; Tian M; Zhao B
Zhonghua Jie He He Hu Xi Za Zhi; 2008 Jan; 31(1):46-50. PubMed ID: 18366907
[TBL] [Abstract][Full Text] [Related]
20. Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity.
Woo SJ; Kim CH; Park MY; Kim HS; Sohn HJ; Park JS; Kim HJ; Oh ST; Kim TG
Cancer Sci; 2008 May; 99(5):1034-9. PubMed ID: 18294279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
